B
lood transfusion is critical to the management of obstetric hemorrhage (OH) and other obstetric emergencies. Globally, OH is a leading contributor to obstetric morbidity and mortality. [1] [2] [3] A lack of early recognition of risk factors for recurrent OH, 3 coupled with the failure to provide effective peripartum care, contribute to adverse maternal outcomes. 2 Consequently, both OH and high rates of blood transfusion administered for OH are primarily encountered in resource-poor countries including South Africa. 4, 5 Although both the International Confederation of Midwives and the International Federation of Gynecology and Obstetrics recommend that there be "blood transfusion facilities in all centers that provide comprehensive health care," 2 little research has been conducted on peripartum blood utilization and its predisposing risk factors.
In one review of the unavailability of transfusion and its contribution to maternal mortality in sub-Saharan Africa, 1 only two articles from South Africa 6,7 were cited, neither of which was within the preceding decade nor, specifically, related to blood utilization. Obstetric transfusion also accounts for a substantial proportion of blood utilization in sub-Saharan Africa, placing a burden on blood collection organizations that struggle to meet demand. A better understanding of blood utilization and antecedent risk factors could identify deficiencies in transfusion practice and reduce preventable and inappropriate transfusions. There is strong evidence that restrictive transfusion practice confers comparable or even superior clinical outcomes to those of liberal transfusion. 8, 9 Research on transfusion in human immunodeficiency virus (HIV)-positive obstetric patients is particularly relevant, given the association of HIV with anemia and other complications, but such data are limited. 10 The few published studies evaluating the association between HIV and increased blood use have yielded somewhat different results. [10] [11] [12] While HIV may be a driver of transfusion, 11, 12 the strength of that association dissipates after controlling for potential confounders. 10 There still remains uncertainty as to why HIV would increase transfusion incidence, if indeed an independent association holds true. Because of their relevance to obstetric practice, HIV treatment, and blood demand, we therefore sought to characterize risk factors for peripartum blood transfusion in a large study of peripartum South African women with very high HIV prevalence.
MATERIALS AND METHODS

Study design
We hypothesized that HIV status and prenatal anemia were independent predictors of peripartum transfusion even after controlling for potential confounders such as parity, mode of delivery, and advanced maternal age. These obstetric services serve a generally urban, lowincome, Black-African and Colored (denotes a specific mixed-race population group) population with high HIV prevalence. CHB and KEH each have both second-tier and tertiary obstetric services while MMH and GSH are linked by referral in a single secondary and tertiary system, respectively. This affords broad representation both by population as well as obstetric pathology, with management of uncomplicated deliveries as well as complex referrals from primary-level hospitals and midwife obstetric units.
The study received ethical approval from the committees representing each of the participating hospitals in addition to the University of California San Francisco, the South African National Blood Service, and the datacoordinating center (RTI International). Written informed consent was obtained from all enrolled participants; deferred consent was allowed for patients who were not able to provide consent at time of transfusion. Once stable, the patients were approached and enrolled under full informed consent. In the event that they declined, any blood samples or associated data were discarded.
Study population
All peripartum obstetric patients with an index hospitalization at a participating hospital during the enrollment period were eligible for enrollment in the study. The study population was restricted to women with pregnancies of at least 26 weeks' gestation; in South Africa, delivery in obstetric patients less than 24 to 26 weeks is managed separately by gynecology as abortion or miscarriage. Stillborn and early neonatal deaths were included as were both normal vaginal delivery and births by Cesarean section. Eligible participants were identified through daily review of ward admission logs and maternity, delivery, and operating room registers; this approach was complemented by direct communication with the blood bank and ward staff. We excluded patients who were transferred or discharged before consent and enrollment could be performed. We also excluded minors (aged < 18 years old) because South African law requires parental or guardian consent for participation in research and it was not feasible to obtain it. From previous data, minors constituted about 2.5% of those patients who sustained OH and/or were transfused. 12 Cases (target, 1200) included women who were transfused (allogeneic red blood cells [RBCs] , platelets [PLTs], or plasma) in the peripartum period, namely, 48 hours before or after delivery. Controls comprised a random sample of nontransfused deliveries (target, 2400), which were stratum matched by hospital and date of delivery, that is, women who were admitted during the peripartum period, being of at least 26 weeks' gestation at time of delivery and not transfused during the peripartum period. This sample size and the 2:1 ratio of controls to cases was chosen to achieve 80% power to detect an odds ratio (OR) of 1.25 for the association between HIV infection and transfusion, our primary hypothesis.
Data collection
Demographic information, medical and obstetric history, HIV status and treatment, OH, and transfusion data were abstracted from the medical records. Machine-readable paper forms (available on request) allowed automated data entry; the electronic data were subsequently transferred to the data-coordinating center for cleaning and analysis.
According to the protocol, complete blood counts and coagulation studies ][international normalized ratio [INR] , prothrombin time [PT], activated partial thromboplastin time [APTT], D-dimers) were to be performed on all cases and 50% of controls; CD4 and HIV viral load were obtained in those patients who were HIV positive. We used a planned missing data design to randomly sample half of the nontransfused women to obtain blood samples. 13 Laboratory procedures differed between cases and controls because of logistics and timing of sample collection. For cases, additional tubes of blood were collected by the clinical staff before transfusion, under a waiver of consent because the laboratory measures of interest (e.g., PT and APTT) are not valid if drawn after transfusion. If the patient later agreed to participate in the study, the tubes were relayed to the laboratory for testing; if not, they were destroyed. For controls, a single EDTA tube was collected at time of enrollment, which was usually the day after delivery.
Definitions
Notable definitions include "OH," which was defined as any obstetric-related hemorrhage occurring in the peripartum period; the World Health Organization (WHO) definition of peripartum hemorrhage was applied, that is, at least 500 mL of blood loss for vaginal delivery or at least 1000 mL of blood loss for Cesarean section. We also used a convenience definition for OH, namely, whether OH was recorded in the medical record, regardless of estimated blood loss. "Booked" and "unbooked" refer to patients who had accessed or not accessed prenatal care, respectively. The prenatal hemoglobin (Hb) value was the lowest recorded measured Hb during prenatal care; because these data were available only from booked women the two variables were considered together. The pretransfusion Hb level refers to the last Hb level that was obtained before the first blood product being transfused.
At the time of the study the national policy regarding the prevention of mother-to-child transmission of HIV was to administer three-drug antiretroviral therapy (ART) to all HIV-positive pregnant patients independent of CD4 count. If a patient was diagnosed in labor a modified ART drug regimen was administered with follow-up after delivery.
Statistical analysis
Cases and controls were compared using counts and percentages for categorical data and means and distributions for continuous variables. For categorical data, counts and percentages for single variables and combinations of variables were produced, using chi-square tests of significance. For the continuous data, distributions were examined individually and stratified by covariates, using t tests to test differences between means.
Because PLT count was intended to be collected from only one-half of the controls 13 but was also missing on a smaller proportion of controls and cases, we sought to impute the data using multiple imputation by chained equations methodology implemented in the "mice" package 14 Several different graphical diagnostics were used to check whether the distribution of the imputed data was similar to that of the observed data. 18 The mice package was used to analyze the imputed data; this enables repeated imputation inferences as described in Rubin. 19 This methodology accounts for the uncertainty associated with the imputed data and incorporates this uncertainty into the variance estimates.
Multiple logistic regression was used to model the relationship between case versus control status and the predictor variables, controlling for potential confounding variables. A larger set of variables was initially considered. The model was refined using Bayesian information criterion to identify the best model, and the final model was based on all the significant variables. Once the final set of variables was identified, two-way interactions were investigated but none of them were included in the final model.
RESULTS
Of 1534 potentially eligible cases, 316 (20.6%) were deemed ineligible (transfusion was not administered; age less than 18 years), 11 (0.7%) refused, 1206 consented, and 1200 had complete clinical data. Of 2509 potentially eligible controls, 28 (1.1%) were deemed ineligible, 44 (1.8%) refused, 2437 consented, and 2434 had complete clinical data. Thus the final data set included 1200 cases and 2434 controls. During the period in which cases and controls were enrolled, 61,405 births were reported at the participating hospitals including 34,188 vaginal deliveries and 27,217 (44%) Cesarean sections. Overall, 1097 (30.6%) of combined cases and controls were HIV positive, of whom 108 (9.8%) had CD4 counts of less than 200 3 10 6 cells/L.
Of those women who were HIV positive 992 (90.4%) reported being on ART before delivery or prevention of mother-to-child transmission regimen during delivery. Transfused cases and controls were evenly distributed by hospital, consistent with our matching criteria (Table 1) , and did not differ by age or race: most patients (84.3%) were aged 18 to 34 years and of black race/ethnicity (82.5%). Cases were more likely than controls to have had no prenatal care (10.2% vs. 2.7%; p < 0.0001) while rates of Cesarean delivery did not differ significantly from those of controls (Table 2) . Cases were much more likely than controls to have had OH either by clinical mention of the diagnosis (67.4% vs. 4.3%; p < 0.0001) or by application of the WHO definition based on estimated blood loss (43.6% vs. 4.5%; p < 0.0001). Nadir prenatal Hb values were lower among cases than controls, with 53.2% of cases and 79.2% of controls having Hb values of 10 g/dL or higher (p < 0.0001). Neither gravidity nor parity differed between cases and controls. Cases were more likely than controls to be HIV positive (35.4 vs. 28.3%; p < 0.0001), to have missing CD4 lymphocyte counts, and to have lower CD4 lymphocyte counts (p < 0.0001). Transfused cases were more likely than controls to have pregnancies with shorter gestational age (p < 0.0001) and lower birthweights (p < 0.0001). Two (0.17%) deaths were recorded in the transfused group (0.04%) and one death was reported in the control (nontransfused group); mortality status was missing in 155 subjects (4.27%). Among transfused cases, the mean pretransfusion Hb level recorded in medical records was 7.5 g/dL (standard deviation [SD], 1.75g/dL) ranging from 7.3 g/dL (MMH) to 7.8 g/dL (KEH), and mean posttransfusion Hb level was 9.2 g/dL (SD 1.74g/dL) ranging from 9.0 g/dL (KEH) to 9.6 g/dL (CHB; Fig. 1 ). The median interval between the pretransfusion Hb level and the first transfusion was less than 1 day. The mean number of RBC units administered per transfusion was 2.0 (SD, 1.25), ranging from 1. (Table 3) , the strongest risk factors for transfusion were several subtypes of OH, most notably antepartum hemorrhage including placenta previa and abruptio placentae (OR, 198) and hemorrhage associated with vaginal delivery including retained placenta, uterine atony, and vaginal lacerations (OR, 136). Other risk factors for transfusion included prenatal anemia (ORs, 23, 9.48, 6.12, and 3.25 for prenatal Hb level of less than 7, 7-7.9, 8-8.9, and 9-9.9 g/ dL, respectively), whether the patient accessed prenatal care (OR, 6.71 for "unbooked" patients), and PLT count (ORs, 4.10, 2.66, 1.77, and 1.06 for count of less than 50 3 10 
DISCUSSION
In addition to recognized causes of OH, the study reveals several potentially modifiable risk factors for peripartum blood transfusion in South Africa. Prenatal anemia, access to prenatal care, and the hospital of birth can potentially be addressed by improved prenatal care and or implementation of transfusion protocols to standardize practice. We also identified novel biologic risk factors for transfusion including moderately low PLT count and HIV infection that persisted even after controlling for potential confounding. Finally, HIV prevalence was very high, with prevalence of almost 35% among cases and 28% among controls; however, a high rate of ART coverage was observed, consistent with the national rollout of ART.
Antepartum hemorrhage due to abruptio placenta or placenta previa (OR, 198) was somewhat more strongly associated with transfusion than were complications associated with vaginal delivery including retained placenta, uterine atony, and vaginal lacerations (OR, 136), although CIs overlapped. In contrast, bleeding in association with Cesarean section carried comparatively lower odds of transfusion (OR, 40). These data may be helpful to obstetricians in determining when to order blood preemptively. Regarding practice differences, the association between transfusion risk and one of the four hospitals, as well as a higher Hb increment per unit transfused at the same hospital, suggest some degree of inappropriate transfusion. Redoubled efforts to implement existing South African guidelines for obstetric transfusion could reduce unnecessary transfusion.
Women with a prenatal Hb value less than 7 g/dL had estimated odds of transfusion approximately 23 times higher than those with Hb values of 10 g/dL or more, and intermediate Hb values carried intermediate levels of risk consistent with a "dose response." Among women with OH, 14% received 4 or more RBC units consistent with severe hemorrhage but the majority received only 1 or 2 RBC units consistent with an interplay between OH and anemia as predisposing to transfusion as indicated by our multivariable model. This finding suggests that anemic women are less able to tolerate even small to moderate hemorrhage during delivery and argues strongly that better interventions to diagnose and correct prenatal anemia need to be developed and tested. Physiologic anemia results from the relative increase in the plasma volume (50%) versus RBC mass (25%) in pregnancy. 20, 21 Iron deficiency anemia is the most common cause of prenatal anemia in South Africa. 22 While gastrointestinal iron absorption increases with gestational age, dietary intake is insufficient in 20% of pregnancies to prevent iron deficiency anemia in the absence of supplementation. 21 In one study, the prevalence of prenatal anemia at a regional hospital in South Africa was 42%; a significant difference in prevalence was noted between HIV-positive and HIVnegative pregnant women (71.3% vs. 28.7%, respectively; p < 0.0001).
23
Low gestational age has been shown to be a risk factor for peripartum transfusion. 24 In our study, low gestational age and lower birthweights were associated with peripartum transfusion in bivariate analysis but not the final multivariable model. Gestational age and birthweight are related indicators for diverse maternal (e.g., anemia, hypertension), fetal (e.g., genetic or developmental anomalies, intrauterine growth retardation), and placental (e.g., placenta previa, abruptio, placental insufficiency) pathologies. 25 We believe that underlying reasons for low birthweight and prematurity (e.g., abruptio and placenta previa) may contribute to peripartum hemorrhage and transfusion.
Although the association between HIV status was modest compared to the other major drivers of peripartum transfusion, HIV-positive women were still almost 30% more likely to be transfused in the peripartum period than HIV-negative women. The reasons for this independent risk are not clear. HIV-related anemia, altered transfusion practice in HIV patients, and HIV-related coagulopathy were considered as possible contributors. Residual confounding between HIV-related anemia and transfusion is possible, but we controlled for prenatal Hb in the multivariable model. Whether physicians' transfusion practice differs for HIV-positive patients is difficult to determine. Although we found no difference in pretransfusion Hb or Hb increment according to HIV status, acuity of illness may have been greater in the HIV patients as indicated by a higher temperature and lower mean arterial PLTs/L. Prevailing wisdom derived from oncology studies suggests that only very low PLT counts (<20 3 10 9 PLTs/L) are associated with bleeding, but higher PLT counts may be needed in the setting of hemorrhage. 26 Other potential explanations for the apparent association include physician practice or a dilutional effect on PLT count due to fluid replacement given before transfusion. Another potential explanation is that the lower PLT count is an effect of rather than the cause of bleeding. There were limitations to the study. Foremost was the low compliance with collection of pretransfusion blood samples from cases (range by hospital, approx. 6%-36%), stemming from our reliance on housestaff to collect the blood samples. The low compliance raises the possibility of selection bias in that patients for whom blood samples were available may have been sicker or healthier than those without data. Second, risk factor data were limited by the chart abstraction process and the accuracy of source data and as a result may have been missing or inaccurate. Finally, our study was restricted to four obstetric services. Although the participating sites are major obstetric services, the findings may not be generalizable to all deliveries. Specifically, the high rate of Cesarean sections at these secondary and/or tertiary referral centers probably does not represent all deliveries. Conversely, low-risk births were more likely to deliver at midwife clinics and data from rural hospitals were not captured and remain an important, yet neglected, area of study. However, we did represent the geographic and socioeconomic characteristics of most South African births.
In conclusion, blood transfusion is integral to obstetric resuscitation and progress to attainment of the sustainable Development Goal 3 to reduce, by 2030, the global maternal mortality ratio to less than 70 per 100 3 10 9 live births. 27 Blood transfusion is also a limited resource in much of Africa where transfusion demand often cannot be met. 28 Our findings suggest that minimization of obstetric RBC transfusions in South Africa may require different approaches than those being adopted in high-income countries. [29] [30] [31] [32] Strategies to mitigate the morbidity of specific causes of OH have already been adopted within the obstetric community. There may still be scope for improvement with other measures (e.g., tranexamic acid) that have shown to be beneficial in management of OH. 33 The earlier diagnosis and better treatment of prenatal anemia, possibly including intravenous iron therapy, is an intervention that could probably have substantial impact on transfusion incidence. Regarding clinical practice, clinical trials of transfusion thresholds are needed in the African obstetric population to develop evidencebased guidelines similar to that which have been used to direct practice in other patient groups. 31 Finally, the wider rollout of ART in South Africa may obviate HIV infection's influence on transfusion risk and additional research is needed to confirm our finding that moderately low PLT count impact transfusion risk.
